Navigation Links
Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
Date:10/3/2007

Supports Genaera's Strategic Focus on Core Programs in Obesity and Asthma

PLYMOUTH MEETING, Pa., Oct. 3 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced that MacroChem Corporation (OTC Bulletin Board: MACM) has exercised the July 2007 option to acquire from Genaera the exclusive worldwide license rights for use of pexiganan as a drug. Pexiganan is a novel, small peptide anti-infective originally discovered by Genaera scientists which was developed for the treatment of patients with infected diabetic foot ulcers.

Under the terms of the license agreement, MacroChem has agreed to pay Genaera an initial fee of $1 million dollars in several installments through February 1, 2008. The terms of the agreement also include $7 million dollars in milestone payments to Genaera upon the achievement of clinical milestones including the start of phase 3 clinical trials and regulatory approval. The agreement further includes sales-based milestones of up to $35 million dollars, and 10% royalty payments on net sales. In addition, MacroChem will assume all clinical development, manufacturing and regulatory activities for pexiganan.

"We are pleased to enter into this agreement with MacroChem for the therapeutic rights to pexiganan. We believe pexiganan has significant potential to treat infected diabetic foot ulcers and that MacroChem, with its complementary pipeline and focus, is an excellent partner to move pexiganan forward to commercialization," stated Dr. Henry Wolfe, Executive Vice President and Chief Scientific Officer.

"Out-licensing of pexiganan is an important first step in the execution of Genaera's strategy to divest our non-core assets, which also include squalamine and LOMUCI
'/>"/>

SOURCE Genaera Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Genaera Discontinues Lomucin in Cystic Fibrosis Studies
2. Chiron Corporation Gets US Contract To Produce Bird Flu Vaccines
3. PM announces a new health care order for India
4. Ramdoss Announces Introduction of RCH-II
5. Britain Announces Third Transfusion Related Mad Cow Case
6. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
7. Tibet Announces the Dalai Lama’s Tour of South Americ
8. NHS announces further Cost cutting Measures
9. Indian PM Announces Of Setting Up India Study Center At Tashkent
10. PowderMed Announces Needle-Less Flu Vaccine
11. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
Post Your Comments:
*Name:
*Comment:
*Email: